294 related articles for article (PubMed ID: 27700619)
1. Translating nanoparticulate-personalized cancer vaccines into clinical applications: case study with RNA-lipoplexes for the treatment of melanoma.
Grabbe S; Haas H; Diken M; Kranz LM; Langguth P; Sahin U
Nanomedicine (Lond); 2016 Oct; 11(20):2723-2734. PubMed ID: 27700619
[TBL] [Abstract][Full Text] [Related]
2. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.
Kranz LM; Diken M; Haas H; Kreiter S; Loquai C; Reuter KC; Meng M; Fritz D; Vascotto F; Hefesha H; Grunwitz C; Vormehr M; Hüsemann Y; Selmi A; Kuhn AN; Buck J; Derhovanessian E; Rae R; Attig S; Diekmann J; Jabulowsky RA; Heesch S; Hassel J; Langguth P; Grabbe S; Huber C; Türeci Ö; Sahin U
Nature; 2016 Jun; 534(7607):396-401. PubMed ID: 27281205
[TBL] [Abstract][Full Text] [Related]
3. Synthetic multiepitope neoantigen DNA vaccine for personalized cancer immunotherapy.
Yang X; Fan J; Wu Y; Ma Z; Huang J; Zhang Y; Zhou Z; Mo F; Liu X; Yuan H; Xu Y; Pan L; Chen S
Nanomedicine; 2021 Oct; 37():102443. PubMed ID: 34303839
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells.
Speiser DE; Pittet MJ; Rimoldi D; Guillaume P; Luescher IF; Liénard D; Lejeune F; Cerottini JC; Romero P
Semin Cancer Biol; 2003 Dec; 13(6):461-72. PubMed ID: 15001165
[TBL] [Abstract][Full Text] [Related]
5. Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach.
Lu Y; Wang Y; Miao L; Haynes M; Xiang G; Huang L
Cancer Lett; 2016 Aug; 379(1):32-8. PubMed ID: 27235608
[TBL] [Abstract][Full Text] [Related]
6. Transcutaneous delivery of DNA/mRNA for cancer therapeutic vaccination.
Sun X; Zeng L; Huang Y
J Gene Med; 2019 Jul; 21(7):e3089. PubMed ID: 30958606
[TBL] [Abstract][Full Text] [Related]
7. Personalized vaccines for cancer immunotherapy.
Sahin U; Türeci Ö
Science; 2018 Mar; 359(6382):1355-1360. PubMed ID: 29567706
[TBL] [Abstract][Full Text] [Related]
8. Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination.
Vormehr M; Schrörs B; Boegel S; Löwer M; Türeci Ö; Sahin U
J Immunol Res; 2015; 2015():595363. PubMed ID: 26844233
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy at large: the road to personalized cancer vaccines.
Vonderheide RH; Nathanson KL
Nat Med; 2013 Sep; 19(9):1098-100. PubMed ID: 24013748
[No Abstract] [Full Text] [Related]
10. Recent progress in mRNA cancer vaccines.
Yao R; Xie C; Xia X
Hum Vaccin Immunother; 2024 Dec; 20(1):2307187. PubMed ID: 38282471
[TBL] [Abstract][Full Text] [Related]
11. Actively personalized cancer vaccines--the step into clinical application.
Kloke BP; Kreiter S; Vormehr M; Diken M; Kuhn AN; Sahin U
Pharmazie; 2016 Jan; 71(1):43-7. PubMed ID: 26867352
[TBL] [Abstract][Full Text] [Related]
12. Personalized approaches to active immunotherapy in cancer.
Ophir E; Bobisse S; Coukos G; Harari A; Kandalaft LE
Biochim Biophys Acta; 2016 Jan; 1865(1):72-82. PubMed ID: 26241169
[TBL] [Abstract][Full Text] [Related]
13. Mannosylated and histidylated LPR technology for vaccination with tumor antigen mRNA.
Pichon C; Midoux P
Methods Mol Biol; 2013; 969():247-74. PubMed ID: 23296939
[TBL] [Abstract][Full Text] [Related]
14. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine.
Hsueh EC; Morton DL
Semin Cancer Biol; 2003 Dec; 13(6):401-7. PubMed ID: 15001158
[TBL] [Abstract][Full Text] [Related]
15. Type I Interferons Interfere with the Capacity of mRNA Lipoplex Vaccines to Elicit Cytolytic T Cell Responses.
De Beuckelaer A; Pollard C; Van Lint S; Roose K; Van Hoecke L; Naessens T; Udhayakumar VK; Smet M; Sanders N; Lienenklaus S; Saelens X; Weiss S; Vanham G; Grooten J; De Koker S
Mol Ther; 2016 Nov; 24(11):2012-2020. PubMed ID: 27506450
[TBL] [Abstract][Full Text] [Related]
16. Making It Personal: Neoantigen Vaccines in Metastatic Melanoma.
Hellmann MD; Snyder A
Immunity; 2017 Aug; 47(2):221-223. PubMed ID: 28813655
[TBL] [Abstract][Full Text] [Related]
17. Tumor antigens and tumor vaccines: peptides as immunogens.
Slingluff CL
Semin Surg Oncol; 1996; 12(6):446-53. PubMed ID: 8914209
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of cancer with dendritic cells loaded with tumor antigens and activated through mRNA electroporation.
Van Nuffel AM; Corthals J; Neyns B; Heirman C; Thielemans K; Bonehill A
Methods Mol Biol; 2010; 629():405-52. PubMed ID: 20387165
[TBL] [Abstract][Full Text] [Related]
19. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA.
Weide B; Carralot JP; Reese A; Scheel B; Eigentler TK; Hoerr I; Rammensee HG; Garbe C; Pascolo S
J Immunother; 2008; 31(2):180-8. PubMed ID: 18481387
[TBL] [Abstract][Full Text] [Related]
20. Mathematical model of a personalized neoantigen cancer vaccine and the human immune system.
Rodriguez Messan M; Yogurtcu ON; McGill JR; Nukala U; Sauna ZE; Yang H
PLoS Comput Biol; 2021 Sep; 17(9):e1009318. PubMed ID: 34559809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
